iHealthScreen wins FDA clearance for automated retinal screening
iPredict-DR has received FDA 510(k) clearance for automated detection of more-than-mild diabetic retinopathy from retinal images.
Medical AI becomes much more consequential when it moves from demonstration into a cleared clinical workflow.
What happened
iHealthScreen received FDA 510(k) clearance for iPredict-DR, AI software designed to automatically detect more-than-mild diabetic retinopathy in adults with diabetes who have not previously been diagnosed with the condition.
The software analyses colour retinal fundus images captured with a specified retinal camera and is now commercially available in the U.S.
Why it matters
Diabetic-retinopathy screening is a strong AI use case because the workflow is image-based and early detection can determine which patients need further assessment.
Automated analysis could make screening easier to integrate into routine care settings where specialist access is limited.
The important caveat is that FDA clearance does not mean the system replaces ophthalmologists or independently proves better patient outcomes.
The bigger picture
Healthcare AI is moving from experimental models toward regulated products embedded in care pathways.
The strongest opportunities may be narrow systems with a clearly defined input, output and clinical escalation path. iPredict-DR fits that pattern.